Searched for
DR LAL PATHLAB
Dividends & bonus issues: LIC, Asian Paints among 35 stocks turning ex-record date this week. How many do you own?Around 35 companies, including LIC, HUL, Asian Paints and IndusInd Bank, have fixed record dates for dividends, bonus issues and buybacks i...- JioBlackRock Flexi Cap Fund exits Adani Enterprises, Adani Ports and 3 other companies; adds Tata Motors and 14 more stocksJioBlackRock Flexi Cap Fund exited Adani Enterprises, Adani Ports and three other stocks in May while adding Tata Motors and 14 new stocks ...
- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian equities extended gains for a third straight session, with Sensex and Nifty rising on optimism over the Iran-US peace framework and ...
- Sunil Singhania-backed Abakkus Small Cap Fund adds 3 new stocks, increases stake in HDFC Bank, SBI and 49 othersSunil Singhania's Abakkus Small Cap Fund added three new stocks in May, including Tanla Platforms and Intellect Design Arena. The fund also...
- Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...
- Smallcaps continue to draw domestic flows, stock selection key: Sandip SabharwalIndian equity markets show resilience post-election results. Market expert Sandip Sabharwal notes that governance and policy continuity are...
- Dr. Lal Pathlabs among 5 stocks showing bullish RSI upswingFive stocks from the Nifty500 universe were flagged in the RSI Trending Up scan on May 4 after gaining over 4%. The indicator turned positi...
- Positive Breakout: These 14 stocks cross above their 200 DMAsAs long as the stock is priced above the 200-day SMA on the daily timeframe, it is generally considered to be in an overall uptrend.
- Forget the noise: These 54 smallcap stocks attracted FII buying in March quarterForeign institutional investors are strategically buying into beaten-down smallcap stocks in India, increasing stakes in 54 companies despi...
- Add Dr Lal Pathlabs, target price Rs 2,910: HDFC SecuritiesHDFC Securities has an 'add' call on Dr Lal Pathlabs with a target price of Rs 2910. The company reported a total income of Rs 621.80 crore...
- JM Financial upgrades Dr Lal Pathlabs to Buy, target price Rs 3,600JM Financial recommends buying Dr. Lal Pathlabs with a target price of Rs 3,600, citing a potential 25% upside. The company's Q3 earnings s...
- Buy Dr. Lal Pathlabs, target price Rs 3181: BNP Paribas SecuritiesDr. Lal Pathlabs Ltd., incorporated in the year 1995, is a Mid Cap company (having a market cap of Rs 19103.91 Crore) operating in Hospital...
- Dr Lal PathLabs Q2 Results: Net profit rises 53%YoY to Rs 111 croreDr Lal PathLabs reported a Rs 72 crore net profit during the corresponding period of the previous year. Revenues rose 12.6% to Rs 601 crore...
- Dr Lal PathLabs Q3 Results: Net profit drops 8% to Rs 54 croreDr Lal PathLabs said its emphasis is on improving the market penetration through franchisee model, and leveraging the digital infrastructur...
- Dr Lal PathLabs Q1 Results: Net profit dips 57% to Rs 58 croreThe company had reported a net profit of Rs 134 crore in the April-June period of the last fiscal.Revenue from operations declined to Rs 50...
- Dr Lal Pathlabs skids 3% as Q3 net profit drops 39% YoYThe company’s EBITDA (earnings before interest, tax, depreciation and amortization) dipped 21.3 per cent to Rs 109 crore in Q3 FY22 over Rs...
- Dr Lal PathLabs Q1 results: Net profit declines 52% to Rs 28.4 croreThe company had posted a net profit of Rs 59.1 crore for the corresponding period of the previous fiscal, Dr Lal PathLabs said in a filing ...
- Buy Dr. Lal Pathlabs, target Rs 1,249: Dharmesh ShahBuy Dr. Lal Pathlabs Ltd. at a price target of Rs 1249.0 and a stoploss at Rs 1136 from entry point.
- Nomura upgrades Dr Lal PathLabs to 'buy' from 'neutral'The brokerage said growth in recent times in Dr Lal PathLabs has been hit by demonetisation but it remains constructive on long term growth...
- Buy Dr. Lal Pathlabs, target Rs 1180 : Edelweiss Financial ServicesThe brokerage forecasts revenue and EBITDA to grow at CAGR of 21% each, over FY16-19 and RoCE to stabilise around 38 40% post launching new...
Load More
